Novavax’s Seasonal Influenza VLP Vaccine Candidate Shows Positive Results In A Phase II Clinical Trial In Older Adults
Novavax, Inc. (Nasdaq: NVAX) reported that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age...
(more...)
(more...)
